Determinants of mortality among postmenopausal women in the women's health initiative who report rheumatoid arthritis

Arthritis and Rheumatology

Volumn 66, Issue 3, 2014, Pages 497-507

  Kuller, Lewis H ^a   Mackey, Rachel H ^a   Walitt, Brian T ^b   Deane, Kevin D ^c   Holers, V Michael ^c   Robinson, William H ^d   Sokolove, Jeremy ^d   Chang, Yuefang ^a   Liu, Simin ^e   Parks, Christine G ^f   Wright, Nicole C ^g   Moreland, Larry W ^a  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c UNIVERSITY OF COLORADO   (United States)

^d STANFORD UNIVERSITY   (United States)

^e BROWN UNIVERSITY   (United States)

^f NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^g UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; METHOTREXATE; RHEUMATOID FACTOR;

ABNORMAL LABORATORY RESULT; ADULT; AGED; ANTIBODY BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; FEMALE; FOLLOW UP; HIGH RISK PATIENT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MIDDLE AGED; MORTALITY; POSTMENOPAUSE; PREDICTIVE VALUE; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SELF REPORT; YOUNG ADULT;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; FEMALE; HUMANS; MIDDLE AGED; PEPTIDES, CYCLIC; POSTMENOPAUSE; RHEUMATOID FACTOR; SEVERITY OF ILLNESS INDEX; WOMEN'S HEALTH;

EID: 84896296878     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38268     Document Type: Article

References (53)

1. Sokka T, Abelson B, Pincus T. Mortality in rheumatoid arthritis: 2008 update. Clin Exp Rheumatol 2008;26:S35-61.
2. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol 2003;30:1196-202.
3. Avina-Zubieta JA, Choi HK, Sadatsafavi M, Etminan M, Esdaile JM, Lacaille D. Risk of cardiovascular mortality in patients with rheumatoid arthritis: a meta-analysis of observational studies. Arthritis Rheum 2008;59:1690-7.
4. Gabriel SE, Crowson CS, O'Fallon WM. Mortality in rheumatoid arthritis: have we made an impact in 4 decades? J Rheumatol 1999;26:2529-33.
5. Radovits BJ, Fransen J, Al Shamma A, Eijsbouts AM, van Reil PL, Laan RF. Excess mortality emerges after 10 years in an inception cohort of early rheumatoid arthritis. Arthritis Care Res (Hoboken) 2010;62:362-70.
6. Mikuls TR, Saag KG, Criswell LA, Merlino LA, Kaslow RA, Shelton BJ, et al. Mortality risk associated with rheumatoid arthritis in a prospective cohort of older women: results from the Iowa Women's Health Study. Ann Rheum Dis 2002;61:994-9.
7. Bjornadal L, Baecklund E, Yin L, Granath F, Klareskog L, Ekbom A. Decreasing mortality in patients with rheumatoid arthritis: results from a large population based cohort study in Sweden, 1964-95. J Rheumatol 2002;29:906-12.
8. Meune C, Touze E, Trinquart L, Allanore Y. High risk of clinical cardiovascular events in rheumatoid arthritis: levels of associations of myocardial infarction and stroke through a systematic review and meta-analysis. Arch Cardiovasc Dis 2010;103:253-61.
9. Bergstrom U, Jacobsson LT, Turesson C. Cardiovascular morbidity and mortality remain similar in two cohorts of patients with long-standing rheumatoid arthritis seen in 1978 and 1995 in Malmo, Sweden. Rheumatology (Oxford) 2009;48:1600-5.
10. Gonzalez A, Maradit Kremers H, Crowson CS, Nicola PJ, Davis JM III, Therneau TM, et al. The widening mortality gap between rheumatoid arthritis patients and the general population. Arthritis Rheum 2007;56:3583-7.
11. Jacobsson LT, Turesson C, Nilsson JA, Petersson IF, Lindqvist E, Saxne T, et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 2007;66:670-5.
12. Mikuls TR, Fay BT, Michaud K, Sayles H, Thiele GM, Caplan L, et al. Associations of disease activity and treatments with mortality in men with rheumatoid arthritis: results from the VARA registry. Rheumatology (Oxford) 2011;50:101-9.
13. Westlake SL, Colebatch AN, Baird J, Kiely P, Quinn M, Choy E, et al. The effect of methotrexate on cardiovascular disease in patients with rheumatoid arthritis: a systematic literature review. Rheumatology (Oxford) 2010;49:295-307.
14. Choi HK, Hernan MA, Seeger JD, Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 2002;359:1173-7.
15. Pincus T, Sokka T, Wolfe F. Premature mortality in patients with rheumatoid arthritis: evolving concepts [editorial]. Arthritis Rheum 2001;44:1234-6.
16. Kroot EJ, de Jong BA, van Leeuwen MA, Swinkels H, Van Den Hoogen FH, van 't Hof M, et al. The prognostic value of anti- cyclic citrullinated peptide antibody in patients with recent-onset rheumatoid arthritis. Arthritis Rheum 2000;43:1831-5.
17. Van Der Helm-van Mil AH, Verpoort KN, Breedveld FC, Toes RE, Huizinga TW. Antibodies to citrullinated proteins and differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7:R949-58.
18. Sihvonen S, Korpela M, Mustila A, Mustonen J. The predictive value of rheumatoid factor isotypes, anti-cyclic citrullinated peptide antibodies, and antineutrophil cytoplasmic antibodies for mortality in patients with rheumatoid arthritis. J Rheumatol 2005;32:2089-94.
19. Crowson CS, Liang KP, Therneau TM, Maradit Kremers H, Gabriel SE. Could accelerated aging explain the excess mortality in patients with seropositive rheumatoid arthritis? Arthritis Rheum 2010;62:378-82.
20. Davidson A, Diamond B. Autoimmune diseases. N Engl J Med 2001;345:340-50.
21. Pulendran B, Artis D. New paradigms in type 2 immunity. Science 2012;337:431-5.
22. Hueber W, Tomooka BH, Zhao X, Kidd BA, Drijfhout JW, Fries JF, et al. Proteomic analysis of secreted proteins in early rheumatoid arthritis: anti-CCP-citrulline autoreactivity is associated with up regulation of proinflammatory cytokines. Ann Rheum Dis 2007;66:712-9.
23. Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009;373:659-72.
24. Sihvonen S, Korpela M, Laippala P, Mustonen J, Pasternack A. Death rates and causes of death in patients with rheumatoid arthritis: a population-based study. Scand J Rheumatol 2004;33: 221-7.
25. Liang KP, Gabriel SE. Autoantibodies: innocent bystander or key player in immunosenescence and atherosclerosis? J Rheumatol 2007;34;1203-7.
26. Rantapaa-Dahlqvist S, de Jong BA, Berglin E, Hallmans G, Wadell G, Stenlund H, et al. Antibodies against cyclic citrullinated peptide and IgA rheumatoid factor predict the development of rheumatoid arthritis. Arthritis Rheum 2003;48:2741-9.
27. Aggarwal R, Liao K, Nair R, Ringold S, Costenbader KH. Anti-citrullinated peptide antibody assays and their role in the diagnosis of rheumatoid arthritis [review]. Arthritis Rheum 2009; 61:1472-83.
28. Wiik AS, van Venrooij WJ, Pruijn GJM. All you wanted to know about anti-CCP but were afraid to ask. Autoimmun Rev 2010;10: 90-3.
29. Walitt B, Mackey R, Kuller L, Deane KD, Robinson W, Holers VM, et al. Predictive value of autoantibody testing for validating self-reported diagnoses of rheumatoid arthritis in the Women's Health Initiative. Am J Epidemiol 2013;177:887-93.
30. Women's Health Initiative Study Group. Design of the Women's Health Initiative clinical trial and observational study. Control Clin Trials 1998;19:61-109.
31. Lynch CP, McTigue KM, Bost JE, Tinker LF, Vitolins M, Adams- Campbell L, et al. Excess weight and physical health-related quality of life in postmenopausal women of diverse racial/ethnic backgrounds. J Womens Health 2010;19:1449-58.
32. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
33. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
34. McTigue KM, Chang YF, Eaton C, Garcia L, Johnson KC, Lewis CE, et al. Severe obesity, heart disease, and death among white, African-American, and Hispanic postmenopausal women. Obesity 2012. E-pub ahead of print.
35. Eaton CB, Young A, Allison MA, Robinson J, Martin LW, Kuller LH, et al. Prospective association of vitamin D concentrations with mortality in postmenopausal women: results from the Women's Health Initiative (WHI). Am J Clin Nutr 2011;94:1471-8.
36. Satoh M, Chan EK, Ho LA, Rose KM, Parks CG, Cohn RD, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthritis Rheum 2012;64:2319-27.
37. Ware JE Jr, Snow KK, Kosinski M, Gandek B. SF-36 health survey: manual and interpretation guide. Boston: The Health Institute, New England Medical Center; 1993.
38. Padyukov L, Seieslastad M, Ong RT, Ding B, Ronnelid J, Seddighzadeh M, et al, and the Epidemiological Investigation of Rheumatoid Arthritis (EIRA) Study Group. A genomewide association study suggests contrasting associations in ACPApositive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 2011;70:259-65.
39. Greenberg JD, Kremer JM, Curtis JR, Hochberg MC, Reed G, Tsao P, et al, on behalf of the CORRONA Investigators. Tumour necrosis factor antagonist use associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis 2011;70:576-82.
40. Wasko MC, Dasgupta A, Hubert H, Fries JF, Ward MM. Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis [published erratum appears in Arthritis Rheum 2013;65:1231]. Arthritis Rheum 2013;65:334-42.
41. Ridker PM. Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost 2009;7:332-9.
42. Kuller LH, Tracy R, Belloso W, De Wit S, Drummond F, Lane HC, et al, for the INSIGHT SMART Study Group. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med 2008;5:e203.
43. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012;18:1028-40.
44. Sattar N, McCarey DW, Capell H, McInnes IB. Explaining how "high-grade" systemic inflammation accelerates vascular risk in rheumatoid arthritis. Circulation 2003;108:2957-63.
45. Connolly M, Mullan RH, McCormick J, Matthews C, Sullivan O, Kennedy A, et al. Acute-phase serum amyloid A regulates tumor necrosis factor α and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum 2012;64:1035-45.
46. Richards TJ, Kaminski N, Baribaud F, Flavin S, Brodmerkel C, Horowitz D, et al. Peripheral blood proteins predict mortality in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012; 185:67-76.
47. Weyand CM, Fulbright JW, Goronzy JJ. Immunosenescence, autoimmunity, and rheumatoid arthritis. Exp Gerentol 2003;38: 833-41.
48. Michel JJ, Turesson C, Lemster B, Atkins SR, Iclozan C, Bongartz T, et al. CD56-expressing T cells that have features of senescence are expanded in rheumatoid arthritis. Arthritis Rheum 2007;56: 43-57.
49. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet 2012;380:689-98.
50. Nicola PJ, Maradit-Kremers H, Roger VL, Jacobsen SJ, Crowson CS, Ballman KV, et al. The risk of congestive heart failure in rheumatoid arthritis: a population-based study over 46 years. Arthritis Rheum 2005;52:412-20.
51. Young A, Koduri G, Batley M, Kulinskaya E, Gough A, Norton S, et al. Mortality in rheumatoid arthritis: increased in the early course of disease, in ischaemic heart disease and in pulmonary fibrosis. Rheumatology (Oxford) 2007;46:350-7.
52. Falk RH, Comenzo RL, Skinner M. The systemic amyloidoses. N Engl J Med 2007;337:898-909.
53. Wong TC, Meier CG, Testa SM, Klock AM, Aneizi AA, Shakesprere J, et al. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation 2012;126:1206-16.